2023
The Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease
Shi A, Mansour S. The Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease. Nephron 2023, 147: 778-781. PMID: 37611550, PMCID: PMC10841333, DOI: 10.1159/000533415.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAngpt-2 levelsCardiovascular diseaseVascular biomarkersPoor outcomeChronic kidney disease patientsPoor long-term outcomesGrowth factorKidney transplant recipientsOutcomes of patientsKidney disease progressionKidney disease patientsLong-term outcomesPlacental growth factorVascular endothelial growth factorEndothelial growth factorAKI patientsAKI survivorsCardiac complicationsKidney injuryTransplant recipientsCardiac surgeryHeart failureHospitalized patientsEndothelial damageIntegrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes
Bhatraju P, Prince D, Mansour S, Ikizler T, Siew E, Chinchilli V, Garg A, Go A, Kaufman J, Kimmel P, Coca S, Parikh C, Wurfel M, Himmelfarb J. Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes. American Journal Of Kidney Diseases 2023, 82: 311-321.e1. PMID: 37178093, PMCID: PMC10523857, DOI: 10.1053/j.ajkd.2023.01.449.Peer-Reviewed Original ResearchConceptsMajor adverse kidney eventsLong-term outcomesAKI subphenotypesKidney injuryClinical outcomesUrinary biomarkersHigh riskChronic kidney disease progressionLong-term clinical outcomesCox proportional hazards modelAdverse kidney eventsLong-term sequalaeHospital-level factorsKidney disease progressionChronic kidney diseaseKaplan-Meier curvesSerum creatinine concentrationEpithelial cell injuryHeterogeneous clinical syndromeProportional hazards modelLong-term riskAKI patientsAKI subgroupKDIGO stageMedian follow
2022
Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies
Coca SG, Vasquez-Rios G, Mansour SG, Moledina DG, Thiessen-Philbrook H, Wurfel MM, Bhatraju P, Himmelfarb J, Siew E, Garg AX, Hsu CY, Liu KD, Kimmel PL, Chinchilli VM, Kaufman JS, Wilson M, Banks RE, Packington R, McCole E, Kurth MJ, Richardson C, Go AS, Selby NM, Parikh CR. Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies. American Journal Of Kidney Diseases 2022, 81: 190-200. PMID: 36108888, PMCID: PMC9868060, DOI: 10.1053/j.ajkd.2022.08.007.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Acute kidney injuryHeart failureClinical eventsIndex hospitalizationPlasma soluble tumour necrosis factor receptor 1Soluble tumour necrosis factor receptor concentrationsBiomarker measurementsKidney disease incidenceBaseline serum samplesKidney disease progressionLate heart failureTumor necrosis factor receptor 1Association of biomarkersProportional hazards modelNecrosis factor receptor 1Magnitude of associationFactor receptor 1AKI statusIndex admissionKidney eventsKidney outcomesAKI definitionKidney injuryHospital discharge